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INTRODUCTION
The incidence of echinococcosis in European countries var-
ies from 0.1 to 10 cases per 100 000 residents (Eiermann et
al., 1998; Lukmanova et al., 2011; Mosayebi et al., 2013).
The number of cases of echinococcosis diagnosed for the
first time is rather high in Latvia as well, despite a compara-
tively low population size. The location of Latvia next to
endemic regions for this zoonotic disease, for example,
Russia, Belarus, Poland is also an important factor (Eier-
mann et al., 1998, Lukmanova et al., 2011); however, no
targeted studies on the incidence, risk factors, diagnostics
and therapy have been conducted particularly in our coun-
try. Data on the quality of life of patients in cases where
radical surgical extraction of the parasite was impossible,
and on the number of years of medication therapy required,
are also lacking.
The development of cystic, as well as alveolar echinococco-
sis is associated with individual factors of the host organ-
ism, as well as immunological reactions. It is known that
the susceptibility in humans varies, as there are more-
susceptible individuals and non-susceptible or resistant indi-
viduals. This is possibly connected with the major histo-
compatibility complex (MHC) system, which is directly in-
volved in adaptive immune response formation. Since T
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The aim of this study was to assess the relationship between HLA Class II alleles in two groups of
patients in Latvia: patients with cystic and alveolar echinococcosis. The study included 37 pa-
tients from the Rîga East Clinical University Hospital with echinococcosis (29 patients with cystic
echinococcosis and eight patients with alveolar echinococcosis) and 100 healthy control persons
without echinococcosis. HLA Class II allele genotyping was performed using Real-time po-
lymerase chain reaction–sequence specific primer (RT-PCR-SSP). The odds ratios (OR), with
95% confidence intervals (95% CI), were calculated using statistical analysis performed with IBM
SPSS Statistics for Windows, Version 22.0, to evaluate the risk of developing the disease in an
individual having a particular HLA genotype. In the case of cystic echinococcosis a more severe
course of a disease can be anticipated in the presence of HLA-DRB1 alleles *17:01 and *07:01,
-DQB1 *03:02, and *03:01, -DQA1*04:01 and haplotypes HLA-DRB1*04:01/-DQB1*03:01/
-DQA1*03:01, HLADRB1*11:01/ -DQB1*03:01 /-DQA1*05:01. However, in the group with alveolar
echinococcosis it was associated with the HLA-DRB1 alleles *17:01 and *07:01, -DQB1 *05:01
and haplotypes HLA- DRB1*17:01/-DQB1*02:01-2/-DQA1*01:01, HLA-DRB1*11:01/
-DQB1*03:01/-DQA1*01:03 and HLA-DRB1*11:01/-DQB1*03:01/-DQA1*03:01. HLA-
DRB1*15:01/-DQÂ1*06:02-8/-DQA1*05:01 and HLA-DRB1*13:01/-DQB1*02:01-2/-DQA1*05:01
haplotypes were protective in all patient groups. The limitations of this exploratory study indicate
that a broader study needs to be conducted for revealing specific risk and protective HLA Class II
haplotypes for patients with cystic and alveolar echinococcosis in Latvia.
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cells recognise only fragmented antigens displayed on cell
surfaces, antigen processing must occur before the antigen
fragment, bound to the MHC, is transported to the surface
of the cell, a process known as presentation, where it can be
recognised by a T cell receptor. Antigen presentation de-
scribes a vital immune process that is essential for T cell
immune response triggering. MHC-II molecules are respon-
sible for the presentation of peptides to T-lymphocytes,
which initiate the response of different immune system
cells. HLA-DRB1/-DQA1/-DQB1 are the most polymorphic
of the HLA class II genes and therefore can be used for in-
dividual identification. According to literature data, there
are alleles of HLA that are associated with increased risk of
developing a disease and alleles that are associated with de-
creased risk of the progress of the disease (Mosayebi et al.,
2013).
Review of the conducted research on alveolar echinococco-
sis presents various results. The data of a study conducted in
Germany suggest that HLA-DRB1*11 is associated with de-
creased risk of developing alveolar echinococcosis, while
HLA-DQB1*09:01 with faster progression of the disease
(Eiermann et al., 1998). However, in accordance with re-
search conducted in China, HLA-DRB1*04:0x is associated
with increased susceptibility, while HLA-DRB1*07:01 with
resistance (Mosayebi et al., 2013). A study of the Alaskan
population showed that HLA-DRB1*09:01 and HLA-
DRB1*16:01, *16:02 are associated with elevated suscepti-
bility to disease (Mosayebi et al., 2013). In a study con-
ducted in 1998 in Europe, the HLA-DRB1*11 allele group
was associated with reduced risk of disease development,
while HLA-DQB1*02 was more frequently detected in pa-
tients with a progressive course of the disease (Aydinli et
al., 2007). The data of a Turkish study showed that allele
groups HLA-DRB1*15, HLA-DQB1*02, *06, *07 were
most commonly detected in patients, and that HLA-
DQB1*02, *06, *07 was more frequently detected in pa-
tients with a complicated course of the disease (Aydinli et
al., 2007).
The review of research results dealing with cystic echino-
coccosis also presents varying results. Data from a study of
cystic echinococcosis conducted in Iran showed that HLA-
DQB1*03 and HLA-DRB1*11 were associated with de-
creased risk of the development of cystic echinococcosis
(Mosayebi et al., 2013). A study on children in Russia dem-
onstrated that HLA-DRB1*07, -DQB1*09, and -DQB1*02
were associated with elevated risk of the progression of the
disease and HLA-DQB1*02 and -DRB1*03 with a higher
risk of developing a complicated condition (superinfection
of the cyst content with bacterial pathogens) (Lukmanova et
al., 2011). Data from Lebanon showed that HLA-B*14 and
-DRB1*01 alleles were associated with lower risk of con-
tracting the disease, while HLA-B*35 — with high risk; the
researchers noted that their results were similar to those
from Russia (Chakhtoura et al., 2007). In the Saudi Arabia
population, HLA-DR16 and HLA-DR7 alleles were associ-
ated with a higher risk of contracting the disease, while
HLA-DR1 and HLA-DR10 alleles ensured resistance (Hus-
sein et al., 2012). In Yemen, the HLA-DR16 allele was as-
sociated with increased risk of getting infected, and HLA-
DR1, -DR8 and -DR52 alleles with decreased risk (Al-
Ghoury et al., 2010). An Egyptian study also linked HLA-
DR3 with increased risk of developing a complicated course
of the disease (Azab et al., 2004). A Turkish study in a child
population showed that HLA-DR15 and HLA-B44 were as-
sociated with the development of the disease, HLA-B18 and
HLA-DR1 with resistance, and HLA-DR11 with a high prob-
ability of recovery (Yalcin et al., 2010). Taking into ac-
count that antigen presentation by HLA II molecules is an
inductor of specific immune response (Janeway et al., 2001;
Male et al., 2013), it is important, and the aim of this study
was to assess the relationship between HLA Class II alleles
in two groups of patients in Latvia: patients with cystic and
alveolar echinococcosis. This has not been investigated in
many previous studies in European countries and also in
Latvia.
MATERIALS AND METHODS
Patient group. The study involved 144 patients with
echinococcosis in the medical records available at the Rîga
East Clinical University Hospital for the time period from
1 January 1999 to 1 February 2015. During selection, 28 pa-
tients were not included in the study, because the diagnosis
could not be considered to be verified in the presence of
positive serology analyses alone, because cross-reaction
with other flatworm parasites was possible. Also, other pa-
tients were excluded from the study group, because the
finding of a simple cyst (radiologically no signs typical of
echinococcosis were found) in the liver could not be
deemed to be echinococcosis, and furthermore, it is not con-
firmed by serological analyses. Thus, a total of 116 patients
were selected for further analysis.
A total of 37 patients were included in the study of immu-
nogenetic factors affecting the course of the disease (the
study group was limited because 31 patients from the group
died, and 48 patients did not wish to participate for various
reasons). The patients were selected based on the following
criteria: 1) confirmed case of parasitosis — positive sero-
logical finding and characteristic radiological findings
(principally, ultrasound or computed tomography imaging
data); 2) diagnosis occurred between the period of 1999 and
2015; 3) the patient had lived in Latvia for at least 15 years
and was alive; 4) the patient gave their consent to partici-
pate in the study. We used the term “complicated” or severe
course of the disease based on the following criteria: 1)
echinococcosis lesion larger than 10 cm; 2) lesion count 5
or more; 3) inability to use radical treatment and 4) reoccur-
rence of disease after surgical removal of the parasite.
All patients participating in the study were divided into two
groups based on subtype of the parasite — infection of
Echinococcus granulosus and Echinococcus multilocularis,
respectively 29 and 8 patients. Most of the patients (75%)
were females. The mean age of females was 51.1 years and
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55.4 years in males and was not significantly different be-
tween genders.
This study started in October 2015. Approval of the Rîga
Stradiòð University (RSU) Ethics Committee was obtained
to perform this study. Each participant signed an informed
consent to participation and approval of the Central Medical
Ethics Committee, Rîga, Latvia for the genetic analysis was
also obtained.
Methods. HLA-DRB1;-DQA1;-DQB1 typing detection was
performed in the Joint Laboratory of Clinical Immunology
and Immunogenetics of the Rîga Stradiòð University. For
HLA Class II alleles detection, 4 ml of peripheral blood
with EDTA were collected and stored at –20 oC before de-
tection. For human DNA extraction QIAamp® DNA Blood
Kit (Germany) was used in accordance with the methodol-
ogy approved by the manufacturer.
Material from the data base of the Joint Laboratory of Clini-
cal Immunology and Immunogenetics of RSU was used for
the comparison of patient HLA test results with HLA of
healthy blood donors (n = 100) determined in the labora-
tory. This control group included blood donors aged from
18 to 65 years, without HIV infection, viral hepatitis C and
cytomegalovirus infection. No relatives were involved in
this group. In both subsamples, clinical and control, the
same protocol for DNA isolation and HLA typing was ap-
plied. The analysis was conducted in the Joint Laboratory of
Clinical Immunology and Immunogenetics of RSU.
The investigation of HLA class II genotype of each patient
was performed in the Joint Laboratory of Clinical Immunol-
ogy and Immunogenetics of RSU. Peripheral blood samples
(5 ml) were collected in EDTA containing tubes and stored
at –20 °C. The QIAamp® DNA Blood Kit (QIAGEN, Ger-
many) was used for human DNA extraction according to
manufacturer’s instruction (Anonymous, 2016b). DNA am-
plification was performed by Real-Time polymerase chain
reaction (RT-PCR) with low resolution sequence specific
primers (DNA-Technology, Russia) according to manufac-
turer’s instructions (Anonymous, 2018). Each kit contained
an internal control for evaluation of RT- PCR quality and
positive control. HLA typing included identification of
HLA-DRB1* alleles (01 to 18), HLA-DQA1*alleles (01:01,
01:02; 01:03; 01:04, 02:01; 03:01;04:01, 05:01, 06:01), and
HLA-DQB1* alleles (02:01-02:02; 03:01-04; 04:01-04:02;
05:01-04; 05:02-03; 06:01;06:02-08). Amplification was
performed using a Real-Time PCR Thermal Cycler “DT-
Lite” with four channels and 48 wells (DNA-Technology,
Russia). The reaction mixture was subjected to 35 amplifi-
cation cycles, each consisting of denaturation at 94 °C
(60 s), followed by one cycle, annealing at 94 °C (20 s),
67 °C (2 s) followed by seven cycles and extension at 93 °C
(5 s), 65 °C (4 s), with a final extension in step with 35 cy-
cles.
Statistical analysis. IBM SPSS Statistics for Windows,
Version 22.0, was used for the statistical analysis. Frequen-
cies of alleles were compared with the Pearson’s chi-square
test. Data were considered statistically significant when a p
value was less than or equal to 0.05. The odds ratios (OR),
with 95% confidence intervals (95% CI), was calculated us-
ing the Simple Interactive Statistical Analysis (SISA) statis-
tics online (http://home.clara.net/sisa/) website, to evaluate
the risk of an individual developing the disease while hav-
ing a particular HLA type (Anonymous, 2016a).
RESULTS
A quantitative analysis of HLA-DRB1, -DQA1 and -DQB1
alleles of HLA Class II was conducted during immunoge-
netic testing in all patients with echinococcosis, as well as
separately in cystic and alveolar echinococcosis groups.
The predisposition to develop cystic echinococcosis in the
patients group was associated with the HLA-DRB1*17:01
(OR = 4.63; p < 0.000) and HLA-DRB1*07:01 (OR 5.65;
p < 0.004) alleles (Table 1). Moreover, the allele
-DRB1*15:01 (OR = 0.19; p = 0.001) was rarer in the cystic
echinococcosis patient group and significantly more fre-
quent in the control group. The detected HLA-DRB1 differ-
ences were not significant after Fisher’s correction for
-DRB1*01:01, -DRB1*08:01 and -DRB1*13:01 alleles (Ta-
ble 1). Probably, only -DRB1*15:01 has a protective effect
in the pathogenesis of cystic echinococcosis.
The alveolar echinococcosis in the patient group showed
significant association after Fisher correction with the
HLA-DRB1*17:01 (OR = 3.07; p = 0.033) and
-DRB1*07:01 (OR=7.0; p = 0.014) alleles (Table 1), but not
for -DRB1* 11:01 allele (Table 1). Probably, only HLA-
DRB1*17:01 and -DRB1*07:01 alleles have a positive ef-
fect in the pathogenesis of alveolar echinococcosis in the
patient group. The alleles -DRB1*13:01 (OR = 0.39; p =
0.591), -DRB1*15:01 (OR = 0.23; p = 0.106) and
-DRB1*01:01 (OR = 0.78; p = 0.545) were rarer in alveolar
echinococcosis in the patient group and significantly more
frequent in the control group, but the differences were not
significant after Fisher correction (Table 1).
In the patient group, the allele combinations *04:01/*11:01
(OR = 8.75, p = 0.002), *17:01/*13:01(OR = 8.11, p =
0.037) and *11:01/*13:01 (OR = 4.90, p = 0.044) was asso-
ciated with more severe disease presentation. In the cystic
echinococcosis patient group, the allele combination
*04:01/*11:01 (OR = 7.78, p = 0.010) was associated with
a more complicated disease presentation. Also, in the alveo-
lar echinococcosis group, the severity of disease was linked
to three allele combinations *17:01/*13:01 (OR = 16.33,
p = 0.001) (Table 2). We did not identify any protective al-
leles in this group.
Cystic echinococcosis in the patient group was associated
with HLA-DQB1*03:02 (OR = 3.67; p = 0.02) and HLA-
DQB1*03:01 (OR = 2.01; p = 0. 033). Also, the allele
-DQB1*05:01 (OR = 0.25; p = 0.047) and -DQB1*06:02-8
(OR = 0.31; p = 0.013) was more rare in the cystic echino-
coccosis in patients group (Table 3). This suggests that
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HLA-DQB1*05:01 and -DRB1*06:02-8 have a protective
effect in the pathogenesis of cystic echinococcosis in the pa-
tients group, compared to the control group (gf = 0.12 and
0.23).
Alveolar echinococcosis in the patient group showed asso-
ciation with the HLA-DQB1*05:01 (OR = 3.18; p = 0.037)
alleles (Table 3). Probably, only these alleles have risk for
pathogenesis of alveolar echinococcosis. The alleles
-DQB1*03:02 (OR = 8.03; p = 0.643), -DQB1*04:01-2
(OR = 11.48; p = 0.545) and -DQB1*06:02-8 (OR = 1.49;
p = 0.091) were more rare in the alveolar echinococcosis
patients group and more frequent in controls, but the differ-
ences were not significant after Fisher correction (Table 3).
Regarding the HLA-DQB1 allele group, we found that
*03:01/*03:02 (OR = 17.68, p = 0.0004), *02:01-2/*03:01
(OR = 3.84, p = 0.047) and *03:02/*06:02-8 (OR = 4.02,
p = 0.08) allele combinations were linked with severe clini-
cal symptoms in all groups.
In the cystic echinococcosis group, the following genotypes
were related to more severe disease: *02:01-2/*03:01
(OR = 5.17, p = 0.024), *03:01/*03:02 (OR = 33.00, p =
0.014) and *03:02/*06:02-8 (OR = 5.94, p = 0.042), but in
the alveolar echinococcosis group with *03:01/*03:02
(OR = 25.83, p = 0.0004) (Table 4).
For HLA-DQA1 group alleles, in the cystic echinococcosis
group the most frequent and possibly with higher risk for
more severe course of the disease was allele *04:01 (OR =
3.84, p = 0.006), while allele *01:02 (OR = 0.28, p = 0.013)
was rare and possibly protective. Alleles *01:03 (OR =
1.81, p = 0.181) and *02:01 (OR = 1.69, p = 0.204) was less
frequent than in the control group, but without statistical
significance (Table 5).
In the HLA-DQA1 allele group, for alveolar echinococcosis
patients we found that alleles *01:01 (OR = 1.89, p = 0.291)
and *03:01 (OR = 1.48, p = 0.388) were more rare that in
the control group and possibly protective but without statis-
tical significance (Table 5).
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T a b l e 1
PROTECTIVE AND RISK DRB1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR
























*01:01 7 0.12 0.75 0.26-1.87 < 0.516 2 0.13 0.78 0.08-3.67 < 0.545** 31 0.15
*15:01 3 0.05 0.19 0.04-0.63 < 0.001 1 0.06 0.23 0.01-1.58 < 0.106** 45 0.23
* 17:01 15 0.26 4.63 1.91-11.16 < 0.000 3 0.19 3.07 0.91-17.15 < 0.033** 14 0.07
*04:01 7 0.12 1.06 0.36-2.73 < 0.905 2 0.13 1.10 0.55-9.38 < 0.122** 23 0.12
*11:01 14 0.24 1.61 0.73-3.41 < 0.184 5 0.31 2.30 0.58-7.75 < 0.141 33 0.17
*13:01 5 0.09 0.56 0.16-1.56 < 0.243 1 0.06 0.39 0.01-2.76 < 0.591** 29 0.15
*07:01 6 0.10 5.65 1.28-28.03 < 0.004 2 0.13 7.0 0.57-52.99 < 0.014** 4 0.02
*08:01 1 0.02 0.23 0.01-1.60 < 0.110** - - ND - - 14 0.07
*09:01 - - ND - - - ND - - 2 0.01
*10:01 - - ND - - - ND - - 5 0.02
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; CI, confidence interval; p-value (probability);
**An extract cell value is less than 5, used Fisher extract results.
T a b l e 2
IMPORTANT HLA-DRB1 ALLELE COMBINATIONS ASSOCIATED WITH SEVERITY OF DISEASE
Alleles
group
*17:01/*11:01 *17:01/*13:01 *04:01/*11:01 *11:01/*13:01
All patients (n = 37)
gf&OR(p)
0.13 0.05/8.11(0.037) 0.15/8.75 (0.002) 0.09/4.90 (0.044)
Cystic echinococcosis patients (n = 29)
gf&OR(p)
0.17/3.26(0.071) 0.07/7.33(0.640) 0.14/7.78(0.010) 0.054
Alveolar echinococcosis patients (n = 8)
gf&OR(p)
0.03 - - 0.25/16.33(0.001)
Control subjects (n = 100)
gf
0.06 0.01 0.02 0.02
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; p-value (probability).
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T a b l e 3
PROTECTIVE AND RISK DQB1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR




















*02:01-2 13 0.22 1.77 0.78-3.88 < 0.123 2 0.12 0.88 0.09-4.16 < 0.612** 28 0.14
*03:01 19 0.33 2.01 0.98-4.02 < 0.033 6 0.37 2.48 0.69-8.03 < 0.088 39 0.19
*03:02 11 0.19 3.67 1.36-9.66 < 0.002 1 0.06 1.04 0.02-8.03 < 0.643** 12 0.06
*03:03 5 0.09 1.25 0.34-3.9 < 0.077 - - ND - 14 0.07
*04:01-2 1 0.02 0.37 0.01-2.80 < 0.300** 1 0.06 1.41 0.03-11.48 < 0.545** 9 0.04
*05:01 2 0.03 0.25 0.03-1.06 < 0.047 5 0.31 3.18 0.79-10.92 < 0.037 25 0.12
*05:02-4 - - ND - - - ND - - 13 0.06
*06:01 2 0.03 0.61 0.06-2.94 < 0.529** - - ND - - 11 0.05
*06:02-8 5 0.09 0.31 0.09-0.83 < 0.013 1 0.06 0.22 0.01-1.49 < 0.091** 47 0.23
Alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; CI, confidence interval; p-value (probability).
**An extract cell value is less than 5, used Fisher extract results.
T a b l e 4
IMPORTANT HLA-DQB1 ALLELE COMBINATIONS ASSOCIATED WITH SEVERITY OF DISEASE
Alleles
group
*02:01-2/*03:01 *03:01/*03:02 *03:01/*06:02-8 *03:02/*06:02-8
All patients (n = 37)
gf&OR(p)
0.13/3.84 (p = 0.047) 0.08/17.68 (p = 0.000) 0.13 0.08/4.02
(p = 0.008)
Cystic echinococcosis, patients (n = 29)
gf&OR(p)
0.14/5.17 (0.024) 0.07/33. 0 (0.014) 0.17 0.03
Alveolar echinococcosis patients (n = 8)
gf&OR(p)
0.07 0.12 - 0.25/5.22(0.048)
Control subjects (n = 100)
gf
0.03 0.01 0.07 0.03
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability).
T a b l e 5
PROTECTIVE AND RISK DQA1 ALLELES OF HLA CLASS II IN IN-PATIENTS WITH CYSTIC ECHINOCOCCOSIS (n = 29), ALVEOLAR






















*01:01 5 0.09 0.53 0.15-1.49 < 0.211 4 0.25 1.89 0.41-6.77 < 0.291** 30 0.15
*01:02 4 0.07 0.28 0.07-0.82 < 0.013 2 0.12 0.54 0.06-2.49 < 0.417** 42 0.21
*01:03 8 0.14 1.81 0.63-4.79 < 0.181 1 0.06 0.77 0.02-5.57 < 0.635** 16 0.08
*02:01 10 0.17 1.69 0.66-4.01 < 0.204 2 0.12 1.16 0.12-5.58 < 0.552** 22 0.11
*03:01 7 0.12 0.88 0.31-2.23 < 0.777 3 0.19 1.48 0.25-5.88 < 0.388** 27 0.13
*04:01 8 0.14 3.84 1.18-12.31 < 0.006 1 0.06 1.6 0.03-13.35 < 0.506** 8 0.04
*05:01 16 0.26 1.21 0.58-2.43 < 0.578 3 0.19 0.73 0.13-2.82 < 0.451** 48 0.24
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; ND, not defined; OR, odds ratio; CI, confidence interval; p-value (probability).
**An extract cell value is less than 5, used Fisher extract results.
We found association of *01:03/05:01 (OR = 5.65, p =
0.040) and *03:01/05:01 (OR = 3.47, p = 0.031) with se-
vere disease course in all groups and also in the alveolar
echinoccosis group *03:01/*05:01 (OR = 4.23, p = 0.016),
but only for 01:01/02:01 (OR = 10.78, p = 0,044) in the al-
veolar echinoccosis group (Table 6).
Regarding HLA-DRB1*/-DQB1*DQA1* genotypes, we
found that Echinococcus infection in all groups was associ-
ated with the following genotypes:
1) HLA-DRB1*17:01/-DQB1*02:01-2/-DQA1*01:01, gene
frequency 0,0.16, OR = 6.26, p = 0.006; compared with
control group 0.03,
2) HLA-DRB1*04:01/-DQB1*03:01/-DQA1*03:01 gene
frequency 0.22, OR = 6.62, p = 0.001 compared with con-
trol group 0.04 and
3) HLA-DRB1*11:01/-DQB1*03:01/-DQA1*05:01 gene
frequency 0.22, OR = 2.79, p = 0.047 compared with con-
trol group 0.09.
In further analysis, we found that in the cystic echinococco-
sis group, more severe presentation was associated with
presence of the following genotypes:
1) HLA-DRB1*04:01/-DQB1*03:01/-DQA1*03:01, gene
frequency 0.28, OR = 9.14, p = 0.001 in control group 0.04,
2) HLA-DRB1*11:01/-DQB1*06:02-8/-DQA1*01:03, gene
frequency 0,08, OR = 8.74, 0.03, in control group 0.01 and
3) HLA-DRB1*11:01/-DQB1*03:01/-DQA1*05:01 gene
frequency 0.28, OR = 3.85, p = 0.015 compared with con-
trol group 0.09.
In the alveolar echinococcosis group, the following geno-
types were significant:
1) HLA-DRB1*17:01/-DQB1*02:01-2/-DQA1*01:01, gene
frequency 0.75, OR = 97.0, p = 0.000 in control group 0.03,
2) HLA-DRB1*11:01/-DQB1*03:01/-DQA1*01:03, gene
frequency 0.17, OR = 20.63, p = 0.000, control group 0.01
and
3) HLA-DRB1*11:01/-DQB1*03:01/-DQA1*03:01, gene
frequency 0.63, OR = 165.0, p = 0.000, control group 0.01.
Protective haplotypes in all groups were: HLA-
DRB1*15:01/-DQÂ1*06:02-8/-DQA1*03:01 gene fre-
quency 0.03, OR = 0.15, p = 0.027, in control group 0.16
(Table 7).
DISCUSSION
One of the objectives of the study was to determine HLA
Class II allele occurrence among echinococcosis patients
and their association with the severity of the disease. The
literature data on the development of echinococcosis and
immunogenetic factors of patients are limited. In the Pub-
Med database only ten publications could be used, as some
studies were not available in English or Russian, and some
of the original publications could not be obtained.
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T a b l e 6
IMPORTANT HLA-DQA1 ALLELE COMBINATIONS ASSOCIATED WITH SEVERITY OF DISEASE
Alleles group *01:03/*-05:01 *03:01/-*05:01 *01:01/*02:01
All patients (n = 37)
gf&OR(p)
0.08 0.16 0.05
Cystic echinococcosis patients (n = 29)
gf&OR(p)
0.10/5.65(0.040) 0.21/3.47(0.031) -




Control subjects (n = 100)
gf
0.020 0.002 0.03
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability).
T a b l e 7
THREE LOCUS, DRB1/-DQB1/-DQA1, ALLELE DISTRIBUTION IN ECHINOCOCCOSIS AND CONTROL GROUPS
Group
Haplotypes
All patients (n = 37)
gf/OR(p)
Cystic echinococcosis
patients (n = 29)
gf/OR(p)
Alveolar echinococcosis
patients (n = 8)
gf/OR (p)
Control subjects (n = 100)
gf
*11:01/*03:01/*05:01 0.22/2.79(0.047) 0.28/3.85(0.015) - 0.09
*15:01/*06:02-8/*05:01 0.03/0.15(0.027) 0.03/0.19(0.064***) - 0.16
*04:01/*03:01/*03:01 0.22/6.62(0.001) 0.28/9.14(0.001) - 0.04
*13:01/*02:01-2/*05:01 0.03/0.19(0.065***) 0.03/0.24(0.128***) - 0.13
*17:01/*02:01-2/*01:01 0.16/6.26(0.006) - 0.75/97.0(0.000) 0.03
*11:01/*03:01/*01:03 0.11 0.05 0.17/20.63 (0.0001) 0.01
*11:01/03:01/*03:01 0.19 0.03 0.63/165(0.000) 0.01
The alleles in bold are statistically significant (p < 0.05). Gf, gene frequency; OR, odds ratio; p-value (probability).
The results showed that of HLA DRB1 gene alleles, *17:01
and *04:01 were more frequently found in patients with
cystic echinococcosis. The association of allele *04:01 with
increased risk of the disease has been described in China,
but the Chinese publication refers to alveolar echinococco-
sis (Mosayebi et al., 2013). Alleles *01:01 and *15:01
rarely occur among the patients in the cystic echinococcosis
group. Similar observations on the protective action of al-
lele *01:01 are mentioned in studies from Russia (Mosayebi
et al., 2013), Lebanon (Aydinli et al., 2007), Saudi Arabia
(Chakhtoura et al., 2007) and Turkey (Yalcin et al., 2010).
Alleles *17:01 and *11:01 occur more frequently in pa-
tients with alveolar echinococcosis. Contradictory data also
exist: allele *11:01 in a study conducted in Germany was
considered to be protective in the cases of alveolar echino-
coccosis (Eiermann et al., 1998), similar data have been ob-
tained in Turkey (Yalcin et al., 2010), and studies con-
ducted in different European countries suggest that it has a
protective character in case of cystic echinococcosis (Luk-
manova et al., 2011). Allele *01:01 was identified as pro-
tective in the case of alveolar echinococcosis. It must be
added that results similar to those in our study have been
obtained from the nearest regions, for example, Europe or
Russia, while partially differing data originate from Asian
countries. These differences are potentially due to genetic
differences in race.
Our study of HLA-DQB1 alleles indicated that allele *03:02
is significantly more frequent among cystic echinococcosis
patients, and allele *03:01 in the alveolar echinococcosis
patient group. These results contradict those in literature
from Iran, where this allele was directly associated with a
lower risk of cystic echinococcosis development (Mosayebi
et al., 2013), which could be explained by genetic differ-
ences.
The analysis of HLA-DQA1 alleles showed that allele
*04:01 was significantly more frequent among cystic
echinococcosis patients, while allele *01:01 was less com-
mon. No significant differences in allele frequency was
found in the patient group with alveolar echinococcosis.
The available literature lacked information on the associa-
tion of alleles HLA-DQA1 with echinococcosis. The data
obtained by us here could be used in similar studies in other
Baltic States, as well as European Union countries, which
could expand the data base used for the detection of simi-
larities and differences.
In-depth analysis in the patient groups examined showed
that the following haplotypes were associated with a more
severe course of disease in the cystic echinococcosis group:
HLA-DRB1*04:01/-DQB1*03:01/-DQA1*03:01, and
HLA-DRB1*11:01/-DQB1*03:01/-DQA1*05:03. The fol-
lowing genotypes were more frequent in the alveolar
echinococcosis group: HLA- DRB1*17:01/
-DQB1*02:01-2/-DQA1*01:01, HLA-DRB1*11:01/
-DQB1*03:01/-DQA1*01:03 and HLA- DRB1*11:01/
-DQB1*03:01/-DQA1*03:01 gene frequency of occurrence
0.63, OR = 165.0, p = 0.000.
The following haplotypes were identified as protective in all
patient groups: HLA-DRB1*15:01/-DQÂ1*06:02-8/
-DQA1*03:01 and HLA-DRB1*13:01/ -DQB1*02:01-2/
-DQA1*05:01.
Immunogenetic data could prove significant for therapy
planning in accordance with the individual characteristics of
a patient, because no data on the optimum duration of ther-
apy and whether the therapy can be terminated without fa-
cilitating the relapse of the infection are currently available.
It is known that there are patients, in whom the disease is
progressing slowly and does not create serious complica-
tions, but it must be kept in mind that there is a group of pa-
tients, in whom even a brief suspension of therapy can lead
to a rapid increase in the activity of parasitic process.
CONCLUSIONS
In the event of cystic echinococcosis a more severe course
of a disease can be anticipated in the presence of HLA-
DRB1 alleles *17:01 and *07:01, -DQB1 *03:01 and 03:02,
-DQA1*04:01 and haplotypes HLA-DRB1*04:01/
-DQB1*03:01/-DQA1*03:01, HLA-DRB1*11:01/
-DQB1*03:01/-DQA1*05:01.
In the event of alveolar echinococcosis a more severe
course of a disease can be anticipated in the presence of





In the event of cystic echinococcosis HLA-DRB1 alleles
*15:01,-DQB1*05:01 and *06:02-8, -DQA1 *01:02 can be
considered as protective. In the event of alveolar echinococ-
cosis HLA-DRB1 alleles *01:01, *15:01 and *13:01, HLA-
DQB1*06:02-8, HLA-DQA1*01:02 and *05:01 can be con-
sidered to be protective, but these differences were not sig-
nificant. The following haplotypes were identified as pro-
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HLA ALÇÏU IZPLATÎBA PACIENTIEM AR CISTISKO UN ALVEOLÂRO EHINOKOKOZI LATVIJÂ
Ir zinâms, ka ehinokokozes attîstîba ir saistîta ar daþâdiem faktoriem, kas ir gan saimniekorganisma, tostarp imûnìençtiski, gan parazîta.
Balstoties uz pieejamajiem datiem, var secinât, ka cilvçku vidû uzòçmîba pret ðo parazitozi ir daþâda, kâ arî slimîbas gaita ir atðíirîga. Ðî
pçtîjuma mçríis bija izpçtît sakarîbas starp HLA II klases alçlçm divâs pacientu grupâs — ar cistisko un alveolâro ehinokokozi, dati tika
salîdzinâti ar veselâm kontroles grupas personâm. Darba rezultâtâ secinâjâm, ka cistiskâs ehinokokozes gadîjumâ smagâka slimîbas gaita ir
saistâma ar HLA-DRB1 alçlçm *17:01 un *07:01, -DQB1 *03:01 un *03:02, -DQA1*04:01 un sekojoðiem haplotipiem HLA-
DRB1*04:01/-DQB1*03:01/-DQA1*03:01, HLA-DRB1*11:01/-DQB1*03:01/-DQA1*05:01. Alveolârâs ehinokokozes gadîjumâ tâs bija
HLA-DRB1 alçles *17:01 un *07:01 , -DQB1*05:01 un haplotipi HLA-DRB1*17:01/-DQB1*02:01-2/-DQA1*01:01,
HLA-DRB1*11:01/-DQB1*03:01/-DQA1*01:03 un HLA-DRB1*11:01/-DQB1*03:01/ -DQA1*03:01. Ðâdi haplotipi var tikt uzskatîti par
protekt îviem abâs sl imîbas grupâs HLA-DRB1*15:01/-DQÂ1*06:02-8/-DQA1*05:01 un HLA-DRB1*13:01/
-DQB1*02:01-2/-DQA1*05:01. Jâpiebilst, ka imûnìençtiskie dati var bût nozîmîgi, plânojot terapijas veidu un ilgumu, kas nâkotnç varçtu
bût individualizçts.
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